OverviewSuggest Edit

Pulse Biosciences is a medical technology company developing a novel tissue treatment platform based on its proprietary Nano-Pulse Stimulation technology. Nano-Pulse Stimulation is a non-thermal, precise, focal drug-free tissue treatment technology that initiates cell death within treated tissue. NPS utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles. Once created, these transient nanopores allow ions to pass through these membranes, which disrupts cellular function and initiates cell death. NPS cell death eliminates treated tissue cells with a minimal inflammatory response, leading to a favorable healing process and the replacement of treated tissue cells with healthy tissue cells.

TypePublic
Founded2014
HQHayward, CA, US
Websitepulsebiosciences.com
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)82(+52%)
Job Openings15
Share Price (Apr 2021)$22.9(-1%)
Cybersecurity ratingAMore

Key People/Management at Pulse Biosciences

Darrin R. Uecker

Darrin R. Uecker

Chief Executive Officer, President & Director
Kenneth A. Clark

Kenneth A. Clark

Director
Ed Ebbers

Ed Ebbers

Executive Vice President and General Manager, Dermatology
Richard Nuccitelli

Richard Nuccitelli

Chief Science Officer
Sandra A. Gardiner

Sandra A. Gardiner

Executive Vice President and Chief Financial Officer
David Danitz

David Danitz

Vice President of Engineering
Show more

Pulse Biosciences Office Locations

Pulse Biosciences has an office in Hayward
Hayward, CA, US (HQ)
3957 Point Eden Way
Show all (1)

Pulse Biosciences Financials and Metrics

Pulse Biosciences Revenue

USD

Net income (FY, 2020)

(49.9m)

EBIT (FY, 2020)

(49.9m)

Market capitalization (6-Apr-2021)

596.9m

Closing stock price (6-Apr-2021)

22.9

Cash (31-Dec-2020)

12.5m

EV

595.8m
Pulse Biosciences's current market capitalization is $596.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cost of goods sold

600.0k600.0k500.0k

General and administrative expense

2.9m15.5m20.0m22.3m22.9m

R&D expense

6.0m9.6m17.3m25.0m26.4m

Operating expense total

8.9m25.1m37.3m47.3m49.3m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

528.0k642.0k893.0k1.2m3.8m4.2m5.4m5.2m5.7m4.4m5.1m5.6m5.6m5.3m

R&D expense

990.0k1.5m1.7m1.9m2.3m3.2m3.2m4.0m5.0m5.8m6.3m6.2m6.2m5.9m

Operating expense total

1.5m2.1m2.6m3.1m6.1m7.4m8.6m9.1m10.7m10.2m11.5m11.8m11.8m11.2m

Depreciation and amortization

166.0k166.0k166.0k166.0k167.0k166.0k166.0k167.0k166.0k167.0k166.0k166.0k166.0k167.0k
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

2.1m3.4m51.1m6.9m12.5m

Prepaid Expenses

412.0k779.0k1.0m1.9m

Inventories

268.0k

Current Assets

16.7m38.5m60.4m26.4m22.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.8b)(25.6m)(37.5m)(47.0m)(49.9m)

Depreciation and Amortization

167.0m1.0m1.3m1.2m665.0k

Inventories

12.0k

Accounts Payable

29.0k517.0k490.0k646.0k(266.0k)
USDQ1, 2016

Financial Leverage

1.1 x
Show all financial metrics

Pulse Biosciences Operating Metrics

FY, 2016

Patent Applications

61

Patents Issued

49
Show all operating metrics

Pulse Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Pulse Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Pulse Biosciences Online and Social Media Presence

Embed Graph

Pulse Biosciences Company Culture

  • Overall Culture

    A+

    95/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Pulse Biosciences News and Updates

Pulse Biosciences Blogs

NEWS ARTICLE: Pulse’s CellFX for Dermatologic Applications

NEWS ARTICLE: Pulse’s CellFX for Dermatologic Applications renanjeff.lila… Wed, 04/14/2021 - 13:21 NEWS ARTICLE: Pulse’s CellFX for Dermatologic Applications 03/01/21 This release is a backfill from a News Wire News …

Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results

Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results Content Import Mon, 02/22/2021 - 16:06 Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results 02/22/21 This release is a backfill from a News Wire …

Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch

HAYWARD, Calif. --(BUSINESS WIRE)--Feb. 19, 2021-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellFX ® procedures in the European Union were successfully completed.

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System®

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System® Content Import Tue, 02/16/2021 - 08:02 Pulse Biosciences Announces Start of Controlled Launch of the CellFX System® 02/16/21 This release is a backfill from a News Wire …

Pulse Biosciences Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for February 22, 2021

Pulse Biosciences Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for February 22, 2021 Content Import Fri, 02/12/2021 - 08:01 Pulse Biosciences Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for February 22, 2021 …

Pulse Biosciences, Inc. Announces At-The-Market Equity Offering Program

HAYWARD, Calif. --(BUSINESS WIRE)--Feb. 4, 2021-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation ™ (NPS ™ ) technology, today announced that it has filed a prospectus supplement with the
Show more

Pulse Biosciences Frequently Asked Questions

  • When was Pulse Biosciences founded?

    Pulse Biosciences was founded in 2014.

  • Who are Pulse Biosciences key executives?

    Pulse Biosciences's key executives are Darrin R. Uecker, Kenneth A. Clark and Ed Ebbers.

  • How many employees does Pulse Biosciences have?

    Pulse Biosciences has 82 employees.

  • Who are Pulse Biosciences competitors?

    Competitors of Pulse Biosciences include Nurami Medical, Tethis and Stem Cell & Device Laboratory.

  • Where is Pulse Biosciences headquarters?

    Pulse Biosciences headquarters is located at 3957 Point Eden Way, Hayward.

  • Where are Pulse Biosciences offices?

    Pulse Biosciences has an office in Hayward.

  • How many offices does Pulse Biosciences have?

    Pulse Biosciences has 1 office.